, EMA ; les deux ne s'entendant pas sur l'étendue des éléments pouvant être considérés comme confidentiels. L'EMA annonça sa décision de publier
, Merck demanda une injonction pour empêcher l'EMA de divulguer les rapports
, L'injonction fut accordée
, Merck mettait en avant 5 arguments : 1. que les rapports étaient protégés au titre de l'Article 4(2) et (3) du règlement n°1049/2001 en raison de la présomption de confidentialité
, que les rapports étaient confidentiels dans leur intégralité selon l'article 4(2° du règlement n°1049/2001 parce qu'ils dévoilent des savoir faires, des aptitudes aux essais cliniques et la stratégie innovante de Merck dans la façon de mener des essais cliniques
, que les intérêts respectifs n'ont pas fait l'objet d'un juste équilibre
, que si l'EMA avait réalisé un juste équilibre entre les intérêts respectifs la décision aurait été en faveur de Merck
Merck et condamna Merck à payer les frais de l'EMA en plus des siens. 3.2.3.3. Pari Pharma v EMA, pp.235-250 ,
, Pari pharma avait obtenu une AMM pour Vantobra®, un produit bénéficiant de la désignation de médicament orphelin
EMA a accordé l'accès au rapport d'évaluation du CHMP sur la supériorité clinique et la similarité de Vantobra® et un produit existant ,
, Pari Pharma a obtenu une injonction pour s'opposer à la divulgation. Paris Pharma a demandé réparation de son préjudice et l'annulation de la décision de l'EMA
, Pari Pharma mettait en avant 5 arguments : 1. Qu'il existe une présomption générale de confidentialité des rapports du CHMP dans le contexte d'une procédure de demande d'AMM selon les règlements n°726, 2004.
, , 2018.
, Opinion | Transparency Hasn't Stopped Drug Companies From Corrupting Medical Research. The New York Times
,
, , 1992.
, A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction, JAMA, vol.268, issue.2, pp.240-248
Ensuring trial validity by data quality assurance and diversification of monitoring methods, Clin Trials Lond Engl, vol.5, issue.1, pp.49-55, 2008. ,
, , 2017.
, A systematic review of the processes used to link clinical trial registrations to their published results, Syst Rev, vol.6, issue.1, p.123
Adjusting for multiple testing-when and how?, J Clin Epidemiol, vol.54, issue.4, pp.343-352, 2001. ,
, , 2001.
, betrayal. baltimoresun.com
, , 2018.
, Misrepresentation and distortion of research in biomedical literature, Proc Natl Acad Sci, vol.115, issue.11, pp.2613-2622
, , 2013.
, Alltrials v the ABPI: a prescription for bad PR. The Guardian
, Testing Treatments: Better Research for Better Healthcare. 2 e éd, 2011.
, , 2014.
, Increasing value and reducing waste: addressing inaccessible research, Lancet Lond Engl, vol.383, issue.9913, pp.257-66
, , 2017.
in published biomedical literature: A methodological systematic review, PLoS Biol, vol.15, issue.9, p.2002173 ,
, Proposal for a regulation of the European parliament and of the council on clinical trials on medicinal products for human use, vol.17, 2012.
, Technical guidance on the format of the data fields of result-related information on clinical trials submitted in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006Rechercher les traductions disponibles de ce lien, 2013.
The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias, Int J Cardiol, vol.40, issue.2, pp.161-167, 1993. ,
Déclaration d'Helsinki de l'AMM-Principes éthiques applicables à la recherche médicale impliquant des êtres humains, 2013. ,
,
Fate of biomedical research protocols and publication bias in France: retrospective cohort study, BMJ, vol.331, issue.7507, p.19, 2005. ,
Linear mixed-effects models for central statistical monitoring of multicenter clinical trials, Stat Med, vol.33, issue.30, pp.5265-79, 2014. ,
, , 2018.
, Unreported Clinical Trial of the Week
,
, , 2018.
A live informatics tool to monitor compliance with FDA requirements to report clinical trial results, p.266452 ,
, , 2015.
): a pioneer of randomised clinical trials and systematic reviews, J R Soc Med, vol.108, issue.6, pp.237-278 ,
Innovation in the pharmaceutical industry: New estimates of R&D costs, J Health Econ, vol.47, pp.20-33, 2016. ,
, Drug companies must come clean. The Times
Bias in meta-analysis detected by a simple, graphical test, BMJ, vol.315, issue.7109, pp.629-663, 1997. ,
Misleading meta-analysis, BMJ, vol.310, issue.6982, pp.752-756, 1995. ,
, , 2014.
Posting of clinical trial summary results in European Clinical Trials Database (EudraCT) to become mandatory for sponsors as of 21, 2014. ,
, , 2010.
, Reboxetine for acute treatment of major depression: systematic review and metaanalysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials, BMJ, vol.341, p.4737
Data fraud in clinical trials, Clin Investig, vol.5, issue.2, pp.161-73, 2015. ,
Clinical trial data for all drugs in current use, BMJ, vol.345, p.7304, 2012. ,
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, 2012. ,
, , 2018.
, Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource, BMJ, vol.362, p.3218
, The COMPare Trials Project, 2016.
Availability of comparative efficacy data at the time of drug approval in the United States, JAMA, vol.305, issue.17, pp.1786-1795, 2011. ,
Therapeutic fashion and publication bias: the case of anti-arrhythmic drugs in heart attack, J R Soc Med, vol.108, issue.10, pp.418-438, 2015. ,
, Harvard Medical School, 2018.
, , 2018.
, European drug agency wins victory over drug companies that wanted to withhold data, BMJ, vol.360, p.604
, , 2016.
, Publication Bias and Nonreporting Found in Majority of Systematic Reviews and Metaanalyses in Anesthesiology Journals, Anesth Analg, vol.123, issue.4, pp.1018-1043
Expression of concern: non-steroidal anti-inflammatory drugs and the risk of oral cancer, Lancet Lond Engl, vol.367, issue.9506, p.196, 2006. ,
Retraction-Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study, Lancet Lond Engl, vol.367, issue.9508, p.382, 2006. ,
Committee to inquire into clinical trials and disclosure of data, 2012. ,
Report published on National Institute for Health and Clinical Excellence, 2013. ,
,
Reporting of 6-Month vs 12-Month Data in a Clinical Trial of Celecoxib, JAMA, vol.286, pp.2398-400, 2001. ,
The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey, CMAJ Can Med Assoc J J Assoc Medicale Can, vol.176, issue.8, pp.1091-1097, 2007. ,
, , 2012.
, Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Off J Eur Union, Commission Guideline-Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article, vol.57
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, BMJ, vol.324, issue.7349, pp.1287-1295, 2002. ,
,
, Harvard Professor's Attack On Pharma's Clinical Trials Is Absurd
,
, Lancet, 2004.
, Is GSK guilty of fraud?, Lancet Lond Engl, vol.363, issue.9425, p.1919
Why the data on all drug trials must be released. The Gardian, 2013. ,
,
The hidden side of clinical trials, 2016. ,
Pharmaceutical industry sponsorship and research outcome and quality: systematic review, BMJ, vol.326, issue.7400, pp.1167-70, 2003. ,
, , 2000.
, COX-2-Selective NSAIDs: New and Improved?, JAMA, vol.284, issue.10, pp.1297-1306
Comparison of registered and published primary outcomes in randomized controlled trials, JAMA, vol.302, issue.9, pp.977-84, 2009. ,
Decision of the European Ombudsman closing his inquiry into complaint 2560/2007/BEH against the European Medicines Agency, 2010. ,
,
, , 2018.
, Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, JAMA Intern Med, pp.2015-2016
, , 2014.
, RReACT goes global: perils and pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results, Pain, vol.155, issue.7, pp.1313-1320
, OMS. 2015. WHO Statement on Public Disclosure of Clinical Trial Results
,
Joint statement on public disclosure of results from clinical trials, 2017. ,
,
Trial Registration Data Set (Version 1.3.1) ,
, , 2014.
, , 2016.
Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions, 1000. ,
, , 2012.
, Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study, BMJ, vol.344, p.7373
, , 2013.
, Bad Pharma: how drug companies mislead doctors and harm patients, Br J Clin Pharmacol, vol.75, issue.5, pp.1377-1386
Response letter to Sile Lane about the EMA draft policy on proactive publication of and access to clinical trial data, 2014. ,
Registration status and outcome reporting of trials published in core headache medicine journals, Neurology, vol.85, issue.20, pp.1789-94, 2015. ,
Trial registration: a great idea switches from ignored to irresistible, JAMA, vol.292, issue.11, pp.1359-62, 2004. ,
DOI : 10.1001/jama.292.11.1359
Exposing the dangers to patients of medical reviews and textbooks that ignore scientific principles, 2009. ,
Gov: a cross-sectional analysis, Trial publication after registration in ClinicalTrials, vol.6, p.1000144, 2009. ,
Design and reporting modifications in industry-sponsored comparative psychopharmacology trials, J Nerv Ment Dis, vol.190, issue.9, pp.583-92, 2002. ,
, , 2000.
, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA, vol.284, issue.10, pp.1247-55
Publication bias: the case for an international registry of clinical trials, J Clin Oncol Off J Am Soc Clin Oncol, vol.4, issue.10, pp.1529-1570, 1986. ,
Quantifying the risk of error when interpreting funnel plots, 2015. ,
Dissemination and publication of research findings: an updated review of related biases, Health Technol Assess Winch Engl, vol.14, issue.8, pp.1-193, 2010. ,
, , 2009.
, A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example, PLOS Med, vol.6, issue.12, p.1000194
Selective publication of antidepressant trials and its influence on apparent efficacy, N Engl J Med, vol.358, issue.3, pp.252-60, 2008. ,
, , 2009.
, Outcome reporting in industrysponsored trials of gabapentin for off-label use, N Engl J Med, vol.361, issue.20, pp.1963-71
, , 2008.
, Moving Towards Transparency of Clinical Trials. Science, vol.319, issue.5868, pp.1340-1342
, European Medicines Agency launches a new version of EudraCT
,
, Portail d'information de la Commission européenne sur la règlementation européenne essais cliniques